Zacks Research Downgrades Sysmex (OTCMKTS:SSMXY) to Strong Sell

Sysmex (OTCMKTS:SSMXY) was downgraded by equities researchers at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Tuesday,Zacks.com reports.

Separately, Citigroup cut Sysmex from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold”.

Sysmex Trading Down 1.9%

OTCMKTS:SSMXY opened at $9.43 on Tuesday. The company has a market cap of $5.94 billion, a PE ratio of 24.82 and a beta of 1.07. The company has a current ratio of 3.26, a quick ratio of 2.46 and a debt-to-equity ratio of 0.12. The company has a 50 day simple moving average of $8.91 and a two-hundred day simple moving average of $9.07. Sysmex has a 12 month low of $8.01 and a 12 month high of $18.10.

Sysmex (OTCMKTS:SSMXY) last released its quarterly earnings results on Thursday, May 14th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). The firm had revenue of $877.92 million for the quarter, compared to the consensus estimate of $862.45 million. Sysmex had a net margin of 7.13% and a return on equity of 7.23%. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. Research analysts forecast that Sysmex will post 0.42 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.